Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration (FDA) clearance to advance its lead multiple sclerosis (MS) candidate, Lucid-MS (Lucid-21-302), into Phase 2 clinical development. The approval of the Investigational New Drug (IND) application allows the company to initiate a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. Trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as soon as possible.
This regulatory milestone is significant because Lucid-MS represents a novel approach to treating MS. Existing therapies primarily focus on modulating the immune system to reduce inflammatory attacks on myelin, the protective sheath around nerve fibers. In contrast, Lucid-MS is designed to provide neuroprotection by directly inhibiting demyelination—the process by which myelin is destroyed. Specifically, it targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical models have demonstrated that Lucid-MS can both prevent and reverse myelin breakdown, which is the underlying mechanism of MS progression.
The FDA's clearance underscores the potential of Lucid-MS to address a critical unmet need in MS treatment. Current disease-modifying therapies can reduce relapse rates and slow disability progression, but they do not repair existing damage. By targeting the root cause of demyelination, Lucid-MS could offer a complementary or alternative strategy that not only halts disease progression but also promotes remyelination, potentially improving neurological function.
Quantum BioPharma has reported that Lucid-MS was well tolerated with a favorable safety profile in prior Phase 1 trials involving healthy participants. The company also stated it had more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which may help fund the upcoming Phase 2 study. The advancement of Lucid-MS into Phase 2 is a critical step in the drug development process, bringing the company closer to potentially delivering a first-in-class therapy to MS patients.
The implications of this FDA clearance extend beyond Quantum BioPharma. If Lucid-MS proves effective in Phase 2 and subsequent trials, it could change the treatment paradigm for MS, shifting focus from immune suppression to neuroprotection and repair. This would be a major advancement for the millions of people worldwide living with MS, offering hope for better long-term outcomes.
For more information, visit the full press release at https://ibn.fm/HyWYH.
